EST GeneDx (WGS) ‘committing widespread fraud’ according to insiders, Grizzly saysMaximize Your Portfolio with Data Driven ...

EST GeneDx (WGS) down 3% after Grizzly Research publishes short report, alleging fraudMaximize Your Portfolio with Data Driven ...

Management expects GeneDx to report: Revenues of at least $299M for full year 2024, an increase of 54% year-over-year vs previous guidance was $284-$290M. Consensus $288.2M..

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for ...

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) and adjusted gross margin of at least 64% (previous guidance was at least ...

GeneDx Holdings Corp. (NASDAQ:WGSWW – Get Free Report) was the target of a large drop in short interest in January.As of January 15th, there was short interest totalling 7,800 shares, a drop of ...

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...

Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024 GeneDx (Nasdaq: WGS), a leader in delivering improved health ...

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports.

“2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to set ...

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of January 14 ...